These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38289091)

  • 21. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.
    Matteson EL; Aringer M; Burmester GR; Mueller H; Moros L; Kolb M
    Clin Rheumatol; 2023 Sep; 42(9):2311-2319. PubMed ID: 37209188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
    Deterding R; Griese M; Deutsch G; Warburton D; DeBoer EM; Cunningham S; Clement A; Schwerk N; Flaherty KR; Brown KK; Voss F; Schmid U; Schlenker-Herceg R; Verri D; Dumistracel M; Schiwek M; Stowasser S; Tetzlaff K; Clerisme-Beaty E; Young LR
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 34164554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
    Inoue Y; Kitamura H; Okamoto M; Ogura T; Nishioka Y; Kuwana M; Taniguchi A; Ito T; Rohr KB; Suda T
    Respir Investig; 2024 Jul; 62(4):589-596. PubMed ID: 38692040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
    Langford B; Diamantopoulos A; Maher TM; Inoue Y; Rohr KB; Baldwin M
    Adv Ther; 2022 Feb; 39(2):1045-1054. PubMed ID: 34957531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.
    Wijsenbeek M; Swigris JJ; Inoue Y; Kreuter M; Maher TM; Suda T; Baldwin M; Mueller H; Rohr KB; Flaherty KR;
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38135442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
    Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
    Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
    Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
    Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
    Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
    Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
    Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
    Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
    Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
    Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
    Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.